摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(2,4-dimethyl-6-(propionyloxy)phenyl)-3-methylbutanoic acid | 1201687-16-2

中文名称
——
中文别名
——
英文名称
3-(2,4-dimethyl-6-(propionyloxy)phenyl)-3-methylbutanoic acid
英文别名
3-(2,4-dimethyl-6-propanoyloxyphenyl)-3-methylbutanoic acid
3-(2,4-dimethyl-6-(propionyloxy)phenyl)-3-methylbutanoic acid化学式
CAS
1201687-16-2
化学式
C16H22O4
mdl
——
分子量
278.348
InChiKey
OFEQNFBGXADKGM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    20
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    63.6
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds 148
    申请人:AstraZeneca AB
    公开号:US08119673B2
    公开(公告)日:2012-02-21
    This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
    本发明涉及一种新型的具有药用价值的化合物,其化学式为(I),特别是一种竞争性抑制剂,可抑制胰蛋白酶样丝氨酸蛋白酶,特别是凝血酶,其作为药物的用途,包含它们的制药组合物和合成路线。
  • Heterocyclic Carboxamides For Use As Thrombin Inhibitors
    申请人:Branalt Jonas
    公开号:US20110130432A1
    公开(公告)日:2011-06-02
    This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production. Formula (I)
    该发明涉及一种新型的具有药用价值的化合物(I) ,特别是一种具有竞争性的胰蛋白酶样丝氨酸蛋白酶抑制剂的化合物,尤其是血栓素,其用作药物,包含它们的制药组合物以及制造它们的合成路线。化学式(I)。
  • Lymph directing prodrugs
    申请人:Monash University
    公开号:US11311512B2
    公开(公告)日:2022-04-26
    The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
    本发明涉及化合物及其用途,特别是以原药形式存在的化合物,这些化合物可促进药剂向淋巴系统的运输,并随后增强母药的释放。
  • NEW HETEROCYCLIC CARBOXAMIDES FOR USE AS THROMBIN INHIBITORS
    申请人:AstraZeneca AB
    公开号:EP2321301A1
    公开(公告)日:2011-05-18
  • LYMPH DIRECTING PRODRUGS
    申请人:Monash University
    公开号:US20170326103A1
    公开(公告)日:2017-11-16
    The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
查看更多